One year in review 2021: novelties in the treatment of rheumatoid arthritis

Clin Exp Rheumatol. 2021 Jul-Aug;39(4):705-720. doi: 10.55563/clinexprheumatol/beucf1. Epub 2021 Jul 5.

Abstract

Management of rheumatoid arthritis (RA) has evolved over the years as a result of better understanding of the role of different therapeutic strategies, as well as following an increasing availability of new disease-modifying antirheumatic drugs. However, the role of patients in sharing decisions, as well as the rules informing precision medicine or the principles to follow in case of specific comorbidities or extra-articular manifestations are still areas for improvement. Moreover, in 2020, the novel Coronavirus disease-19 outbreak has completely changed many attitudes in terms of assessment and treatment paradigms in most clinical diseases, including RA. In this narrative review, the authors report their specific point of view on the management of RA, based on a critical revision of literature published in 2020, focusing on relevant novelties and future research directions.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents* / adverse effects
  • Arthritis, Rheumatoid* / diagnosis
  • Arthritis, Rheumatoid* / drug therapy
  • Arthritis, Rheumatoid* / epidemiology
  • COVID-19*
  • Comorbidity
  • Humans
  • SARS-CoV-2

Substances

  • Antirheumatic Agents